Amgen 2011 Annual Report Download - page 5

Amgen 2011 Annual Report 3
Sean is well qualifi ed for his new responsibilities
given the depth of his R&D experience at Amgen
during the past 10 years and his background in
the industry and as a physician. Michael Severino,
our former vice president, Global Development,
and a seasoned R&D executive with experience
across a wide range of therapeutic areas, will step
into Sean’s former role as senior vice president,
Global Development and Corporate Chief Medical
Offi cer. We are also pleased to have Tony Hooper
join us as head of Global Commercial Operations.
Tony is an experienced global business leader,
having lived on four continents and led commercial
operations in both mature and emerging markets.
With Sean, Tony, Michael, and Jon Peacock, our
chief fi nancial offi cer who joined Amgen in 2010,
we have strengthened our senior leadership
team’s international experience and capability
to help us navigate our entry into new markets
worldwide. In the coming months, we will all
work together to make sure the leadership
transition is seamless.
Growth Should Accelerate in 2012
We are confident 2012 will be a strong year
for Amgen. We expect continued strength in
sales of Enbrel® (etanercept) and Neulasta®
(pegfi lgrastim), strong growth trends for Nplate®
(romiplostim), Sensipar®/Mimpara® (cinacalcet),
and Vectibix® (panitumumab), and increased
momentum for Prolia® (denosumab) and
XGEVA® (denosumab).
Longer-term Prospects for Amgen
While the challenges ahead are real, we’re excited
about the future. Aging populations and a growing
number of patients needing new medicines create
opportunity. Amgen is strong and widely admired
as a leader in our fi eld, and we have the resources
necessary to chart our course scientifically and
operationally. The objectives we are tackling require
the right investments, and we will make them.
The staff of Amgen—more than 17,000
worldwide—represent our competitive advantage.
Their commitment to serve patients is unmatched.
With our solid underlying fundamentals, our
fi nancial strength, the position of our franchises,
our scientifi c assets, and the quality of our team,
Amgen is well positioned to treat more patients
globally, deliver added stockholder value, and
make a meaningful contribution to society.
Kevin W. Sharer
Chairman and Chief Executive Offi cer
Robert A. Bradway
President and Chief Operating Offi cer
February 23, 2012
Kevin Sharer Announces Plans to Retire
On December 15, 2011, Kevin Sharer, chairman and CEO, announced his plan to retire from
Amgen at the end of 2012. To facilitate an orderly transition process, Kevin will step down as
CEO effective May 23, 2012, and remain as chairman of the Company’s Board of Directors
until December 31, 2012, at which time he will retire from the board and from the Company.
Robert Bradway, currently president and chief operating officer, will become CEO on
May 23, 2012. It is the intention of the Board of Directors to elect Robert chairman of the
board when Kevin retires from that position at the end of 2012.
Awards and Recognition
• Denosumab (Prolia® and XGEVA®) receives the
2011 Prix Galien USA Award for Best Biotechnology
Product. Prolia® (denosumab) also receives Prix
Galien awards in Belgium and Germany, where
Nplate® (romiplostim) is also honored.
• In the cover story entitled “Two Brands in One,”
Med Ad News honors denosumab—Prolia® and
XGEVA®—as Best New Medicine.
• Amgen receives Best Biotechnology
Pipeline ranking from both R&D Directions
and Med Ad News.
• Fortune once again lists Amgen as one of the
most-admired drug companies.
• Amgen ranks fi fth among large biotech and
pharmaceutical companies and 16th overall in
The Scientist’s list of Best Places to Work in Industry.
• Science lists Amgen as one of the top
employers in the biopharmaceutical industry.
• Great Place to Work Institute ranks Amgen
as the number two employer in Europe. In other
surveys, Amgen ranks among the top employers
in the Czech Republic, Poland, and Spain and as
the number one employer in Belgium and Greece.